1 insider bought shares over the last 90 days, the latest by Persons Discharging Managerial Responsibilities Social, filed 17 Sept 2026.
Oculis Holding AG is a listed company. Its directors and officers file their transactions with Nasdaq Baltic. Over the twelve months to 24 October 2026, 24 filings were filed, from 2 insiders.
The record shows 5 purchases on the open market, made by 1 insider, against 1 sale by 1 insider. The totals exclude 6 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
Since 2024, the database holds 6 purchases and 2 sales by insiders of the company.
The latest purchase dates back some time: it was published 37 days ago, on 17 September 2026. Most trades are made public on the day they happen. The legal deadline for notifying a trade is three business days (MAR article 19).
These figures are compiled from regulatory filings published by Nasdaq Baltic. They describe what insiders did and are not a recommendation.
FY ended December 2025 · cache
25 of 41 declarations
Oculis Holding AG is a company listed on the XICE market, specializing in the development of innovative ophthalmic treatments. It focuses on therapeutic solutions for unmet ocular diseases.